European Commission approves ROMVIMZA for TGCT treatment - PharmaTimes Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU

#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...

FDA approves Deciphera’s Romvimza for rare tumour type - PharmaTimes Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations

#biopharmaceuticals #DecipheraPharmaceuticals #Romvimza #tenosynovialgiantcelltumours #TGCT #vimseltinib #FDAapprovel #Deciphera #raretumourtype #symptomatictenosynovialgiantcelltumours #tyrosinekinaseinhibitor #CSF1R #CSF1Rinhibitor #MOTIONclinicaltrial
pharmatimes.com/news/fda-app...